Metabolic research
Mazdutide
Lyophilized metabolic research compound
Mazdutide sits in the GLP-1 / glucagon dual-agonist research lane, where interest centers on incretin signaling, energy expenditure, and metabolic markers.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesPour la recherche en laboratoire uniquement. Pas pour un usage humain ou vétérinaire. Non destiné à diagnostiquer, traiter, guérir, atténuer ou prévenir une maladie.
Conserver scellé, froid, sec et protégé des variations de chaleur. Confirmez le stockage spécifique au produit à l'arrivée.
Emballé pour la stabilité du transit avec une assistance aux commandes disponible pour les itinéraires par temps chaud.
Batch-linked certificate support is available through the documentation desk.
Contexte de recherche
Profil de recherche Mazdutide
Mazdutide is studied as a dual agonist at the GLP-1 and glucagon receptors. Research focuses on how those two signaling pathways interact across receptor assays, cyclic-AMP measurements, glucose and lipid markers, energy-expenditure models, pharmacokinetics, and body-mass endpoints. Its receptor profile differs from tirzepatide, which combines GIP and GLP-1 activity, and from retatrutide, which adds GIP activity to a GLP-1 and glucagon framework. Mazdutide is therefore most relevant when the experimental question concerns the balance between incretin signaling and glucagon-receptor biology. Published findings remain specific to the material and conditions used in each cited study.
Mécanisme proposé
Dual agonism at GLP-1R and the glucagon receptor. The proposed model combines GLP-1-related insulin and appetite signaling with glucagon-receptor effects on hepatic metabolism, lipid handling, and energy expenditure.
Effets rapportés dans les études
- Preclinical studies report GLP-1R and GCGR activation, reduced food intake, increased energy expenditure, improved glucose markers, and reduced body mass.
- Controlled human studies reported reductions in body weight and selected glucose, lipid, and liver-fat-related markers.
- Gastrointestinal events and increases in heart rate have been monitored as relevant safety observations in clinical development.
Critères de recherche courants
GLP-1R and GCGR potency, cyclic AMP, glucose and insulin response, energy expenditure, food intake, lipids, liver-fat markers, body mass, heart rate, and pharmacokinetics.
Preuves et limites
The evidence includes receptor assays, animal studies, and controlled human trials. Mazdutide remains a development-stage molecular reference in many jurisdictions.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
Métabolique Peptide de recherche
Retatrutide
Retatrutide is a metabolic research peptide studied as a triple agonist at GIP, GLP-1, and glucagon receptors. Published studies provide receptor-pharmacology and…
- Forme
- Poudre lyophilisée
- Quantité
- 15 mg
Plage de prix : 124.99 $ à 1,062.99 $ Choix des options Ce produit a plusieurs variations. Les options peuvent être choisies sur la page du produit -
Métabolique Peptide de recherche
Tirzepatide
Tirzepatide is a dual GIP / GLP-1 receptor agonist reference point in metabolic research and comparative incretin pharmacology.
- Forme
- Poudre lyophilisée
- Quantité
- 30 mg
Plage de prix : 104.99 $ à 930.99 $ Choix des options Ce produit a plusieurs variations. Les options peuvent être choisies sur la page du produit